Abbisko Therapeutics wins China IND clearance for pan-KRAS inhibitor ABSK211

PUBT · 2d ago
Abbisko Therapeutics wins China IND clearance for pan-KRAS inhibitor ABSK211
  • Abbisko Therapeutics, a subsidiary of Abbisko Cayman, received China NMPA IND clearance for ABSK211, an oral pan-KRAS inhibitor.
  • The clearance supports clinical testing in advanced solid tumors with KRAS alterations.
  • U.S. FDA IND clearance was granted on July 8, enabling a cross-border clinical development program.
  • An open-label Phase I trial is set to start soon to evaluate safety, efficacy, tolerability, pharmacokinetics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12289756), on August 19, 2026, and is solely responsible for the information contained therein.